First products Dutch Public Health Foresight study available in English In 2017, RIVM launched a Trend Scenario, as well as three thematic reports about the future demand for health care, technology and wider determinants of health.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Trend scenario PHF- 2018 identifies societal challenges for the future If historical trends continue unchanged, dementia will be the leading cause of disease burden in 2040 and the main cause of death.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.
RIVM and Olive Foundation open trading to mark the European Cervical Cancer Prevention Week January 20th, the Olive Foundation and RIVM opened AEX trading day in Amsterdam on the occasion of the 9th European Cervical Cancer Prevention Week.
RIVM presents four scenarios on future public health at European Health Forum Gastein On the first day of the 17th European Health Forum Gastein (EHFG), the Dutch National Institute for Public Health and the Environment (RIVM) organises a workshop on ‘Our health in 2040’.
No new MERS patients in the Netherlands Almost two months ago, two Dutch people were diagnosed with the MERS coronavirus.
RIVM forecasting study: a healthier Netherlands with more people living with a chronic disease Dutch people are reaching an increasingly advanced age: in 2030, the life expectancy of men will be 82 years, and of women, 85.